Clinical Trials Logo

Filter by:
NCT ID: NCT03315884 Recruiting - Clinical trials for Atherosclerosis of the Peripheral Arteries

Pilot Randomized Clinical Study of the Iliac Arteries and Common Femoral Artery With Stenting and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery

TASC CD
Start date: December 2017
Phase: N/A
Study type: Interventional

According to the recommendations of the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) statement and the Russian guidelines for limb ischemia treatment (2010), reconstructive surgery is preferred for type D lesions.

NCT ID: NCT03315520 Recruiting - Clinical trials for Relapsed/Refractory Malignant Lymphomas

BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation

BeEAC-1
Start date: January 22, 2016
Phase: Phase 2
Study type: Interventional

Nowadays there is no randomized trials for comparison the effectiveness and tolerability of different conditioning regimens. Bendamustine is a unique chemotherapeutic agent that combines alkilating action of nitrogen mustard and the activity of purine antimetabolite. Bendamustine has shown its effectiveness for the treatment of patients with chronic lymphoproliferative diseases such as chronic lymphocytic leukemia and several indolent lymphomas. The literature also presents evidence of the effectiveness bendamustine in patients with Hodgkin's lymphoma who received multiple lines of prior chemotherapy, including high dose chemotherapy and transplantation of peripheral hematopoietic stem cells. There are also data of using bendamustine as a part of conditioning regimen. In this context, it was planned a study for evaluation the safety and effectiveness of the BeEAC (bendamustine, etoposide, cytarabine, cyclophosphamide) conditioning regimen prior to autologous transplantation of peripheral hematopoietic stem cells for the treatment of relapsed/refractory malignant lymphomas.

NCT ID: NCT03314064 Recruiting - Clinical trials for Infection, Human Immunodeficiency Virus

Phase 4 Study of Dolutegravir (DTG) in Russian Federation

Start date: December 8, 2016
Phase: Phase 4
Study type: Interventional

DTG 50 milligram (mg) tablet was approved for marketing in Russian Federation; however, DTG is not currently available for subjects at Acquired Immune Deficiency Syndrome (AIDS) Centers as it is not available for order and supply via Federal program. This study is an open-label study which will include subjects, who complete taking DTG in studies ING112276, ING113086, ING114915, ING111762, and those subjects who end participation in study 200304 in which they received either DTG or lopinavir/ritonavir (LPV/RTV). DTG will be supplied at a dose of 50 mg once daily to eligible subjects until the subject stops taking DTG or transitions to commercial supply of DTG when available at AIDS Centers via the Federal program. The objective of this study is to bridge the gap between the closure of ING112276, ING113086, ING114915, ING111762 or end of subject's participation in 200304 and the actual availability of commercial DTG at AIDS Centers via Federal program for human immunodeficiency (HIV)-1-infected adult subjects in Russian Federation. The study will also investigate long-term safety of DTG for subjects continuing DTG in Russian Federation.

NCT ID: NCT03309735 Recruiting - Clinical trials for Threatened Miscarriage

Non-interventional Study of Therapy for Threatened Miscarriage

Start date: October 16, 2017
Phase: N/A
Study type: Observational

Study the efficacy and safety of therapy for threatened miscarriage with medicinal products Utrogestan (micronized progesterone), 200 mg capsules (Besins Healthcare SA, Belgium), and Duphaston (Dydrogesterone), 10 mg coated tablets (Abbott Healthcare Products B.V., the Netherlands)

NCT ID: NCT03306732 Recruiting - Cardiac Surgery Clinical Trials

Thiamine Supplementation in High Risk Cardiac Surgery Patients

APPLY
Start date: October 19, 2017
Phase: Phase 4
Study type: Interventional

This pilot trial will evaluate the ability of thiamine to affect on postoperative vasoplegia in high risk cardiac surgery patients

NCT ID: NCT03303521 Not yet recruiting - Hyperkalemia Clinical Trials

A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.

DIALIZE
Start date: November 9, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of ZS in the treatment of hyperkalemia in patients on hemodialysis.

NCT ID: NCT03302689 Recruiting - Pain, Postoperative Clinical Trials

Comparison Levobupivacaine and Ropivacaine for TAP-block After Caesarean Section

Start date: September 25, 2017
Phase: N/A
Study type: Interventional

Randomized, double-blind, controlled trial: a comparison of Levobupivacaine and Ropivacaine for postoperative analgesia using TAP-block Objectives: 1. VAS score during the first 12 hours 2. Determine which drug is more effective for postoperative analgesia in the first 12 hours after surgery 3. Side effects

NCT ID: NCT03302234 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)

Start date: November 24, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo.

NCT ID: NCT03301220 Not yet recruiting - Clinical trials for Smoldering Multiple Myeloma

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Start date: November 8, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).

NCT ID: NCT03301155 Recruiting - Preventive Medicine Clinical Trials

Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity

Start date: October 3, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to obtain additional data on efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children during the peaks of seasonal morbidity. Primary objectives of the study: 1. To assess duration of the period from the first dose of the drug until manifestation of the symptoms of influenza or another acute respiratory viral infection (ARVI) in two groups of subjects receiving preventive therapy with the study drug (Anaferon for children) or Placebo. 2. To compare duration of periods from the first dose of the drug until manifestation of the symptoms of influenza or another ARVI in two groups of subjects (Anaferon for children and Placebo). 3. Based on the comparison of duration of periods from the first dose of the drug until manifestation of the symptoms of the disease in these two groups, to assess efficacy of Anaferon for children for prevention of influenza and other ARVI in children during the peaks of seasonal morbidity and demonstrate superiority of the study drug over placebo. Additional study objectives: 1. To assess and compare percentage of children not falling with influenza or another ARVI in the two groups during 4-, 8- and 12-week course of preventive therapy. 2. To assess and compare percentage of children in the two groups with the symptoms of respiratory or ear-nose-throat bacterial infections requiring antibacterial therapy within 12-week preventive therapy. 3. To assess and compare percentage of children hospitalized with influenza/ARVI or their complications in the two groups within 12-week preventive therapy. 4. Based on collection and analysis of adverse events during the therapy, to obtain additional information on safety of the study drug